In a recent research report, UBS lifts their price targets significantly higher for both oil and natural gas, and needless to say, higher prices should mean more revenue for the top MLPs.
These are four very solid value buys to consider as we move into the second half of what has been a very up and down 2016.
Though gold is the highest it has been in two years, the good thing for investors looking to add some to their portfolio is that some of the top stocks to buy are still…
UBS Dividend Rulers portfolio focuses on stocks with solid dividends that have consistently grown over time, and their performance this year is outstanding.
Every time we have a headline issue that moves markets lower there is opportunity somewhere, and finding that opportunity can make for some solid portfolio gains for patient investors.
After a long malaise, things finally may be headed higher for the MLPs. These four solid stocks pay good distributions and for now may be among the best income ideas.
These four top companies are on sale and are very well positioned in their respective sectors. They all look like outstanding buys for the second half of 2016.
A new Merrill Lynch report offers the firm's top 10 ideas for the third quarter. What we found interesting is the firm's very defensive posture.
Solid dividend-paying stocks make sense for the rest of this year. While it looks like the stress from the Brexit vote is over for the time being, other factors like the political conventions could…
These four Merrill Lynch stock picks run the gamut of risk, but they all have one thing in common, solid payouts with decent growth potential.
One thing the Brexit vote did was to knock down four top European dividend stocks that many of the firms we cover on Wall Street are very positive on.
Despite the nice rally the last two days, the $3 trillion two day sell-off after the Brexit vote was one of the largest on record. While of course it’s always better to hold your…
One thing that always makes for a good rule of thumb when buying stocks is to look for solid companies with good upside potential and products or services, and where the stocks have been…
A rally on Tuesday and strength on Wednesday feels like a welcome relief after two very depressing trading sessions. Still, one thing seems to be assured. The British exit, hence Brexit, from the European Union will…
Most investors know that logically buying the U.S. 30 year Treasury bond at a 2.26% yield makes little sense. Ditto for a 10-year yield under 1.50%. This almost feels particularly painful when you consider that…
What a wild and crazy week for investors. The stock market volatility index jumped up and down as the Brexit decision was finally answered. With the quarter coming to an end, some big insiders decided…
The week of June 24 was given a serious blow by the unexpected Brexit vote. Yes, Britain voted to leave the European Union. But, some companies here in the United States could literally care…
Ever since the infamous Hillary Clinton tweet about pharmaceutical drug pricing, the biotech and specialty pharmaceutical stocks have taken a huge beating. In some cases, the markets have knocked valuations down into almost value…
Two recent Wedbush research reports focus is on health care companies that not only have data that could prove to be huge, but that have both been absolutely hammered over the past year.
Anyway you slice it, the energy run up from the lows has been outstanding, and investors who had the courage to buy back in January and February have been well rewarded.
